Rosmarinic acid potentiates and detoxifies tacrine in combination for Alzheimer's disease
Mingjuan Yang,Xinyu Zhang,Ou Qiao,Haixia Ji,Yi Zhang,Xiaoying Han,Wenzhe Wang,Xia Li,Juan Wang,Lanping Guo,Luqi Huang,Wenyuan Gao
DOI: https://doi.org/10.1016/j.phymed.2022.154600
IF: 6.656
2022-12-13
Phytomedicine
Abstract:Background There is no doubt that Alzheimer's disease (AD) is one of the greatest threats facing mankind today. Within the next few decades, Acetylcholinesterase inhibitors (AChEIs) will be the most widely used treatment for Alzheimer's disease. The withdrawal of the first generation AChEIs drug Tacrine (TAC)/ Cognex from the market as a result of hepatotoxicity has always been an interesting case study. Rosmarinic acid (RA) is a natural compound of phenolic acids that has pharmacological activity for inhibiting Alzheimer's disease, as well as liver protection. Purpose and study design In this study, we determined that RA can reduce the hepatotoxicity of TAC, and both of them act synergistically to inhibit the progression of AD in mice. Methods In addition to the wild type mice (WT) group, the 6-month-old APP/PS1 (APPswe/PSEN1dE9) double-transgenic (Tg) mice were randomly divided into 6 groups: Tg group, TAC group, RA group, TAC+Silymarin (SIL) group, TAC+RA-L (Rosmarinic Acid Low Dose) goup and TAC+RA-H (Rosmarinic Acid High Dose) group. A series of experiments were carried out, including open field test, Morris water maze test, Hematoxylin - Eosin (HE) staining, Nissl staining, biochemical analysis, immunofluorescence analysis, western blotting analysis and so on. Results none Conclusion The potential drug combination that combines rosmarinic acid with tacrine could reduce tacrine's hepatotoxicity as well as enhance its therapeutic effect on Alzheimer's disease.
pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences